Loading…
Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing
Two for-profit dialysis providers control >70% of the US kidney dialysis market. They use their excessive market power to force private insurers to pay nearly 4 times the Medicare rate, earning exorbitant profits for themselves at the expense of the health care system. Both the legislative and ju...
Saved in:
Published in: | Clinical therapeutics 2023-03, Vol.45 (3), p.264-271 |
---|---|
Main Authors: | , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | |
---|---|
cites | cdi_FETCH-LOGICAL-c345t-ae60b1142cca3fd31ea278e8fde690b9deb618db6589ef8e00cb1c7e03546c7a3 |
container_end_page | 271 |
container_issue | 3 |
container_start_page | 264 |
container_title | Clinical therapeutics |
container_volume | 45 |
creator | Boumil, Marcia M. Curfman, Gregory D. |
description | Two for-profit dialysis providers control >70% of the US kidney dialysis market. They use their excessive market power to force private insurers to pay nearly 4 times the Medicare rate, earning exorbitant profits for themselves at the expense of the health care system. Both the legislative and judicial systems have been called on to address this inequity, so far without success.
We examined the history of this issue as set forth in official Centers for Medicare & Medicaid Services, US Department of Health and Human Services, Federal Trade Commission, and other regulatory documents as well as court filings and opinions. We analyzed the legislative efforts to address the problem and the judicial response.
We found that most efforts, to date, have failed. However, a 2022 US Supreme Court decision helps illuminate a path forward, in large part by defining the limits of judicial intervention.
We identify a path forward that would separate the monopolistic players using a multipronged effort involving US Department of Justice, Federal Trade Commission, Office of Inspector General, and states attorneys general. We also caution that, based on our research, the providers could challenge further efforts by deciding to withdraw services in certain areas or refuse to do business with certain insurers, resulting in patients having difficulty accessing dialysis. |
doi_str_mv | 10.1016/j.clinthera.2022.12.002 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2759962101</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0149291822004064</els_id><sourcerecordid>2804281974</sourcerecordid><originalsourceid>FETCH-LOGICAL-c345t-ae60b1142cca3fd31ea278e8fde690b9deb618db6589ef8e00cb1c7e03546c7a3</originalsourceid><addsrcrecordid>eNqFkMFO3DAURa2Kqgy0vwCW2HST1HYSx-4OTaeAQBpUilR1Yzn2C_UoYw92Umn-Ho8GWLBh9bw4777rg9ApJSUllH9blWZwfvwHUZeMMFZSVhLCPqAZFa0sKK3_HKAZobUsmKTiEB2ltCKEVLJhn9BhxRvBWy5m6O8vcN75B-w8noc0Jhx6fO2shy3-4fSwTS59x_d3-G7aRFhDhqY44mXfQ0z4MmwAjwEvvMW3EaweQ9zmlzM58jP62OshwZfneYzufy5-zy-Lm-XF1fz8pjBV3YyFBk66XJgZo6veVhQ0awWI3gKXpJMWOk6F7XJlCb0AQkxHTQukampuWl0do6_73E0MjxOkUa1dMjAM2kOYkmJtIyVn2VtGz96gq_wdn9spJkjNBJVtnal2T5kYUorQq010ax23ihK1069W6lW_2ulXlKmsP2-ePOdP3Rrs696L7wyc7wHIQv47iCoZB96AdRHMqGxw7x55AhDMmfY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2804281974</pqid></control><display><type>article</type><title>Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing</title><source>Elsevier</source><creator>Boumil, Marcia M. ; Curfman, Gregory D.</creator><creatorcontrib>Boumil, Marcia M. ; Curfman, Gregory D.</creatorcontrib><description>Two for-profit dialysis providers control >70% of the US kidney dialysis market. They use their excessive market power to force private insurers to pay nearly 4 times the Medicare rate, earning exorbitant profits for themselves at the expense of the health care system. Both the legislative and judicial systems have been called on to address this inequity, so far without success.
We examined the history of this issue as set forth in official Centers for Medicare & Medicaid Services, US Department of Health and Human Services, Federal Trade Commission, and other regulatory documents as well as court filings and opinions. We analyzed the legislative efforts to address the problem and the judicial response.
We found that most efforts, to date, have failed. However, a 2022 US Supreme Court decision helps illuminate a path forward, in large part by defining the limits of judicial intervention.
We identify a path forward that would separate the monopolistic players using a multipronged effort involving US Department of Justice, Federal Trade Commission, Office of Inspector General, and states attorneys general. We also caution that, based on our research, the providers could challenge further efforts by deciding to withdraw services in certain areas or refuse to do business with certain insurers, resulting in patients having difficulty accessing dialysis.</description><identifier>ISSN: 0149-2918</identifier><identifier>EISSN: 1879-114X</identifier><identifier>DOI: 10.1016/j.clinthera.2022.12.002</identifier><identifier>PMID: 36586768</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>abuse ; Aged ; American Kidney Fund ; Costs and Cost Analysis ; Dialysis ; Federal agencies ; Federal regulation ; fraud ; Funding ; Government programs ; Health care policy ; Health insurance ; Hemodialysis ; Humans ; Insurance coverage ; Insurance premiums ; Interest groups ; Kidney ; Kidney diseases ; Kidneys ; Legislators ; Low income groups ; Market shares ; Medicare ; Medicare Secondary Payor Act ; monopolies ; Nonprofit organizations ; Patients ; Predatory pricing ; Profit margins ; Public health ; Reimbursement ; Renal Dialysis ; Social security ; State laws ; Transplants & implants ; United States</subject><ispartof>Clinical therapeutics, 2023-03, Vol.45 (3), p.264-271</ispartof><rights>2022 Elsevier Inc.</rights><rights>Copyright © 2022 Elsevier Inc. All rights reserved.</rights><rights>2022. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c345t-ae60b1142cca3fd31ea278e8fde690b9deb618db6589ef8e00cb1c7e03546c7a3</cites><orcidid>0000-0003-4075-7684</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27923,27924</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36586768$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Boumil, Marcia M.</creatorcontrib><creatorcontrib>Curfman, Gregory D.</creatorcontrib><title>Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing</title><title>Clinical therapeutics</title><addtitle>Clin Ther</addtitle><description>Two for-profit dialysis providers control >70% of the US kidney dialysis market. They use their excessive market power to force private insurers to pay nearly 4 times the Medicare rate, earning exorbitant profits for themselves at the expense of the health care system. Both the legislative and judicial systems have been called on to address this inequity, so far without success.
We examined the history of this issue as set forth in official Centers for Medicare & Medicaid Services, US Department of Health and Human Services, Federal Trade Commission, and other regulatory documents as well as court filings and opinions. We analyzed the legislative efforts to address the problem and the judicial response.
We found that most efforts, to date, have failed. However, a 2022 US Supreme Court decision helps illuminate a path forward, in large part by defining the limits of judicial intervention.
We identify a path forward that would separate the monopolistic players using a multipronged effort involving US Department of Justice, Federal Trade Commission, Office of Inspector General, and states attorneys general. We also caution that, based on our research, the providers could challenge further efforts by deciding to withdraw services in certain areas or refuse to do business with certain insurers, resulting in patients having difficulty accessing dialysis.</description><subject>abuse</subject><subject>Aged</subject><subject>American Kidney Fund</subject><subject>Costs and Cost Analysis</subject><subject>Dialysis</subject><subject>Federal agencies</subject><subject>Federal regulation</subject><subject>fraud</subject><subject>Funding</subject><subject>Government programs</subject><subject>Health care policy</subject><subject>Health insurance</subject><subject>Hemodialysis</subject><subject>Humans</subject><subject>Insurance coverage</subject><subject>Insurance premiums</subject><subject>Interest groups</subject><subject>Kidney</subject><subject>Kidney diseases</subject><subject>Kidneys</subject><subject>Legislators</subject><subject>Low income groups</subject><subject>Market shares</subject><subject>Medicare</subject><subject>Medicare Secondary Payor Act</subject><subject>monopolies</subject><subject>Nonprofit organizations</subject><subject>Patients</subject><subject>Predatory pricing</subject><subject>Profit margins</subject><subject>Public health</subject><subject>Reimbursement</subject><subject>Renal Dialysis</subject><subject>Social security</subject><subject>State laws</subject><subject>Transplants & implants</subject><subject>United States</subject><issn>0149-2918</issn><issn>1879-114X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><recordid>eNqFkMFO3DAURa2Kqgy0vwCW2HST1HYSx-4OTaeAQBpUilR1Yzn2C_UoYw92Umn-Ho8GWLBh9bw4777rg9ApJSUllH9blWZwfvwHUZeMMFZSVhLCPqAZFa0sKK3_HKAZobUsmKTiEB2ltCKEVLJhn9BhxRvBWy5m6O8vcN75B-w8noc0Jhx6fO2shy3-4fSwTS59x_d3-G7aRFhDhqY44mXfQ0z4MmwAjwEvvMW3EaweQ9zmlzM58jP62OshwZfneYzufy5-zy-Lm-XF1fz8pjBV3YyFBk66XJgZo6veVhQ0awWI3gKXpJMWOk6F7XJlCb0AQkxHTQukampuWl0do6_73E0MjxOkUa1dMjAM2kOYkmJtIyVn2VtGz96gq_wdn9spJkjNBJVtnal2T5kYUorQq010ax23ihK1069W6lW_2ulXlKmsP2-ePOdP3Rrs696L7wyc7wHIQv47iCoZB96AdRHMqGxw7x55AhDMmfY</recordid><startdate>202303</startdate><enddate>202303</enddate><creator>Boumil, Marcia M.</creator><creator>Curfman, Gregory D.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0003-4075-7684</orcidid></search><sort><creationdate>202303</creationdate><title>Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing</title><author>Boumil, Marcia M. ; Curfman, Gregory D.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c345t-ae60b1142cca3fd31ea278e8fde690b9deb618db6589ef8e00cb1c7e03546c7a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>abuse</topic><topic>Aged</topic><topic>American Kidney Fund</topic><topic>Costs and Cost Analysis</topic><topic>Dialysis</topic><topic>Federal agencies</topic><topic>Federal regulation</topic><topic>fraud</topic><topic>Funding</topic><topic>Government programs</topic><topic>Health care policy</topic><topic>Health insurance</topic><topic>Hemodialysis</topic><topic>Humans</topic><topic>Insurance coverage</topic><topic>Insurance premiums</topic><topic>Interest groups</topic><topic>Kidney</topic><topic>Kidney diseases</topic><topic>Kidneys</topic><topic>Legislators</topic><topic>Low income groups</topic><topic>Market shares</topic><topic>Medicare</topic><topic>Medicare Secondary Payor Act</topic><topic>monopolies</topic><topic>Nonprofit organizations</topic><topic>Patients</topic><topic>Predatory pricing</topic><topic>Profit margins</topic><topic>Public health</topic><topic>Reimbursement</topic><topic>Renal Dialysis</topic><topic>Social security</topic><topic>State laws</topic><topic>Transplants & implants</topic><topic>United States</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Boumil, Marcia M.</creatorcontrib><creatorcontrib>Curfman, Gregory D.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database (ProQuest)</collection><collection>Health & Medical Collection (Proquest)</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Health Management Database (Proquest)</collection><collection>PML(ProQuest Medical Library)</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Boumil, Marcia M.</au><au>Curfman, Gregory D.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing</atitle><jtitle>Clinical therapeutics</jtitle><addtitle>Clin Ther</addtitle><date>2023-03</date><risdate>2023</risdate><volume>45</volume><issue>3</issue><spage>264</spage><epage>271</epage><pages>264-271</pages><issn>0149-2918</issn><eissn>1879-114X</eissn><abstract>Two for-profit dialysis providers control >70% of the US kidney dialysis market. They use their excessive market power to force private insurers to pay nearly 4 times the Medicare rate, earning exorbitant profits for themselves at the expense of the health care system. Both the legislative and judicial systems have been called on to address this inequity, so far without success.
We examined the history of this issue as set forth in official Centers for Medicare & Medicaid Services, US Department of Health and Human Services, Federal Trade Commission, and other regulatory documents as well as court filings and opinions. We analyzed the legislative efforts to address the problem and the judicial response.
We found that most efforts, to date, have failed. However, a 2022 US Supreme Court decision helps illuminate a path forward, in large part by defining the limits of judicial intervention.
We identify a path forward that would separate the monopolistic players using a multipronged effort involving US Department of Justice, Federal Trade Commission, Office of Inspector General, and states attorneys general. We also caution that, based on our research, the providers could challenge further efforts by deciding to withdraw services in certain areas or refuse to do business with certain insurers, resulting in patients having difficulty accessing dialysis.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36586768</pmid><doi>10.1016/j.clinthera.2022.12.002</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4075-7684</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0149-2918 |
ispartof | Clinical therapeutics, 2023-03, Vol.45 (3), p.264-271 |
issn | 0149-2918 1879-114X |
language | eng |
recordid | cdi_proquest_miscellaneous_2759962101 |
source | Elsevier |
subjects | abuse Aged American Kidney Fund Costs and Cost Analysis Dialysis Federal agencies Federal regulation fraud Funding Government programs Health care policy Health insurance Hemodialysis Humans Insurance coverage Insurance premiums Interest groups Kidney Kidney diseases Kidneys Legislators Low income groups Market shares Medicare Medicare Secondary Payor Act monopolies Nonprofit organizations Patients Predatory pricing Profit margins Public health Reimbursement Renal Dialysis Social security State laws Transplants & implants United States |
title | Reining in Costs of Kidney Dialysis: US Supreme Court Offers Hope to End Predatory Pricing |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-13T00%3A35%3A30IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Reining%20in%20Costs%20of%20Kidney%20Dialysis:%20US%20Supreme%20Court%20Offers%20Hope%20to%20End%20Predatory%20Pricing&rft.jtitle=Clinical%20therapeutics&rft.au=Boumil,%20Marcia%20M.&rft.date=2023-03&rft.volume=45&rft.issue=3&rft.spage=264&rft.epage=271&rft.pages=264-271&rft.issn=0149-2918&rft.eissn=1879-114X&rft_id=info:doi/10.1016/j.clinthera.2022.12.002&rft_dat=%3Cproquest_cross%3E2804281974%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c345t-ae60b1142cca3fd31ea278e8fde690b9deb618db6589ef8e00cb1c7e03546c7a3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2804281974&rft_id=info:pmid/36586768&rfr_iscdi=true |